Work

Smooth muscle K Ca 3.1 limits plaque progression and alters plaque composition in mice

Year: 2026
Type: preprint
Abstract: Increased expression of K Ca 3.1 has been found in vascular smooth muscle cells (SMC), macrophages, and T cells in atherosclerotic lesions from humans and mice. While the efficacy of pharmacological inhibition and global silencing of K Ca 3.1 in limiting atherosclerosis has been demonstrated, the relative cell-specific contributions of K Ca 3.1 have not been determined. Therefore, we generated a smooth muscle (SMC) specific inducible K Ca 3.1 -/- mouse with global Apoe -/- knockout (iSMKO) and assessed lesion development in the brachiocephalic artery (BCA) of tamoxifen vs. vehicle injected iSMKO mice on a Western diet (WD) for 15 or 40 weeks. In BCAs of iSMKO mice, lesion size and relative stenosis were increased and lumenal area decreased compared to vehicle injected mice. Additionally, iSMKO mice exhibited a significant reduction in SMC and collagen content at 15 weeks and 40 weeks, while macrophage content increased at 40 weeks. RNAseq analysis of BCA samples from tamoxifen and vehicle injected iSMKO mice prior to WD feeding (baseline) indicated increased mitochondrial function and PPAR-dependent signaling, similar to that found in prior studies of global K Ca 3.1 silencing. However, following 15 weeks of WD and induction of disease, these differences were no longer observed. Overall, this study provides the first cell-specific silencing of K Ca 3.1 to elucidate the contribution of K Ca 3.1 in smooth muscle to prior observations of K Ca 3.1 silencing. Our findings reveal both a beneficial role of SMC K Ca 3.1 in limiting plaque size and macrophage infiltration, and a potentially detrimental effect of reducing plaque SMC and collagen content. Combined with previous studies, this raises caution in the use of pharmacological K Ca 3.1 inhibitors in atherosclerosis and highlights the need for cell-specific targeting of K Ca 3.1 in optimizing potential therapies. Highlights Smooth muscle specific genetic knockout of K Ca 3.1 in mice results in larger atherosclerotic plaques with increased macrophage content revealing a beneficial role of smooth muscle K Ca 3.1 in limiting atherosclerotic lesion development. Silencing K Ca 3.1 in smooth muscle leads to a significant reduction in smooth muscle cell and collagen content within the plaques, consistent with a role for K Ca 3.1 in smooth muscle proliferation and medial-to-intimal cell migration during atherosclerosis. Thus, our findings reveal both a beneficial role of SMC K Ca 3.1 in plaque size and macrophage infiltration, and a potentially detrimental effect of reducing plaque SMC and collagen content, resulting in a lesion with characteristics of a more unstable plaque. RNA sequencing predicted similar downstream signaling effects in both SMC-specific and global K Ca 3.1 silencing, including increased mitochondrial function and PPAR signaling, which likely plays a role in inhibiting smooth muscle proliferation and medial-to-intimal migration in atherosclerosis. While global inhibition of K Ca 3.1 has been demonstrated to have beneficial effects on atherosclerosis development, this study highlights the need for cell-specific targeting of K Ca 3.1 to optimize potential therapies.
Language: English
Subfield: Immunology
Open Access status: green
OpenAlex ID: W7234106007
Cites: 50
Cited by:
Related to: 10